MN-166 (ibudilast) Presentations
Progressive Multiple Sclerosis (Progressive MS):
MN-166 (ibudilast) for Progressive MS: SPRINT-MS Phase 2b Trial AAN 2019 Poster – NfL (0.1 MB)
MN-166 (ibudilast) for Progressive MS: SPRINT-MS Phase 2b Trial AAN 2018 Presentation (1.5 MB)
MN-166 (ibudilast) for Progressive MS: SPRINT-MS Phase 2b Trial Disability Data ACTRIMS 2018 Poster (0.4 MB)
MN-166 (ibudilast) for Progressive MS: American Academy of Neurology (AAN) 2015 Poster (0.5 MB)
Amyotrophic Lateral Sclerosis (ALS):
MN-166 (ibudilast) for ALS: International Symposium on ALS-MND 2021 Poster (1.5 MB)
MN-166 (ibudilast) ALS Webinar
MN-166 (ibudilast) for ALS: International Symposium on ALS-MND 2019 Poster (0.8 MB)
MN-166 (ibudilast) for ALS: International Symposium on ALS-MND 2018 Presentation (2.6 MB)
MN-166 (ibudilast) for ALS: American Academy of Neurology (AAN) 2018 Poster (2.2 MB)
MN-166 (ibudilast) for ALS: International Symposium on ALS-MND 2017 Presentation (4.8 MB)
Glioblastoma:
MN-166 (ibudilast) for Glioblastoma: American Society of Clinical Oncology (ASCO) 2017 Poster (10 MB)
Substance Dependence and Addiction:
MN-166 (ibudilast) for Opioid Dependence: American Academy of Neurology (AAN) Poster (0.4 MB)
MN-166 (ibudilast) for Alcohol Dependence: American College of Neuropsychopharmacology (ACNP) Poster (0.7 MB)
MN-166 (ibudilast) News Articles
SPRINT-MS: Ibudilast Shows Unprecedented Slowing of Brain Atrophy in Progressive MS
New Drug Shows Promise in Slowing Progressive MS
MN-166 (ibudilast) Publications
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.
N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.
PMID: 30157388
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators.
Neurology. 2010 Mar 30;74(13):1033-40. doi: 10.1212/WNL.0b013e3181d7d651. Epub 2010 Mar 3.
PMID: 20200338
Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.
Fox RJ.
Neurology. 2010 Mar 30;74(13):1018-9. doi: 10.1212/WNL.0b013e3181d6b165. Epub 2010 Mar 3. No abstract available.
PMID: 20200341
Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia.
Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A.
Neuropharmacology. 2004 Mar;46(3):404-11.
PMID: 14975696
Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons.
Tominaga Y, Nakamura Y, Tsuji K, Shibata T, Kataoka K.
Clin Exp Pharmacol Physiol. 1996 Jun-Jul;23(6-7):519-23.
PMID: 8800577
Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS.
Suzumura A, Ito A, Yoshikawa M, Sawada M.
Brain Res. 1999 Aug 7;837(1-2):203-12.
PMID: 10434004
Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development.
Suzumura A, Ito A, Mizuno T.
Mult Scler. 2003 Dec;9(6):574-8.
PMID: 14664469
Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity.
Yoshioka A, Shimizu Y, Hirose G, Kitasato H, Pleasure D.
J Neurochem. 1998 Jun;70(6):2416-23.
PMID: 9603206
